Copyright
©The Author(s) 2020.
World J Gastroenterol. May 7, 2020; 26(17): 2097-2110
Published online May 7, 2020. doi: 10.3748/wjg.v26.i17.2097
Published online May 7, 2020. doi: 10.3748/wjg.v26.i17.2097
MELD 6-11 (n = 25) | MELD ≥ 17 (n = 25) | P value | |
Age, yr (IQR) | 62 (56-69) | 58 (56-66) | 0.58 |
Male sex, n (%) | 12 (48) | 16 (64) | 0.39 |
BMI (SD) | 26 (6) | 27 (6) | 0.43 |
MELD score (IQR) | 8 (7-10) | 22 (19-24) | < 0.0001 |
Primary disease, n (%) | 0.20 | ||
NASH | 2 (8) | 4 (16) | |
Nutritive toxic | 15 (60) | 9 (36) | |
Hepatitis B | 2 (8) | 2 (8) | |
Hepatitis C | 5 (20) | 4 (16) | |
Other | 1 (4) | 6 (24) | |
Listed for LT, n (%) | 2 (8) | 5 (20) | 0.41 |
Renal replacement therapy, n (%) | 0 (0) | 2 (8) | 0.49 |
Anticoagulants, n (%) | 9 (36) | 11 (44) | 0.77 |
P2Y12–receptor inhibitor | 1 (4) | 0 (0) | |
ASA | 5 (20) | 8 (32) | |
LMWH | 3 (12) | 3 (12) | |
Laboratory parameters | |||
Bilirubin, mg/dL (SD) | 0.9 (0.5) | 5.7 (4.4) | < 0.0001 |
Creatinine, mg/dL (SD) | 0.8 (0.19) | 1.9 (1.5) | < 0.0001 |
Urea, mg/dL (SD) | 28.7 (9.6) | 58.8 (41.6) | < 0.001 |
INR | 1.1 (0.1) | 1.7 (0.6) | < 0.0001 |
aPTT, s (SD) | 30 (3.7) | 35 (7.5) | 0.047 |
Fibrinogen, mg/dL (SD) | 275 (51) | 209 (90) | 0.006 |
Platelet count, 103/µL (SD) | 145 (51) | 138 (49) | 0.60 |
Minimum, 103/µL | 80 | 72 | |
Maximum, 103/µL | 275 | 274 | |
Thrombocytopenia < 150 × 103/µL, n (%) | 16 (64) | 18 (72) | 1.00 |
All patients | MELD 6-11 | MELD ≥ 17 | P value | |
Impedance aggregometry | ||||
AUCADP1, U (IQR) | 43 (30-56) | 45 (30-56) | 42 (29-67) | 0.80 |
AUCADP1< 55 U, n (%) | 34 (68) | 17 (68) | 17 (68) | 0.58 |
AUC ASPI2, U (IQR) | 71 (57-99) | 72 (57-96) | 68 (43-104) | 0.53 |
AUCASPI2 < 79 U, n (%) | 22 (44) | 12 (48) | 10 (40) | 0.94 |
AUCTRAP, U (IQR) | 92 (61-106) | 94 (80-109) | 79 (60-110) | 0.26 |
AUCTRAP < 92 U, n (%) | 24 (48) | 9 (36) | 15 (60) | 0.09 |
Thrombelastometry | ||||
EXTEM | ||||
CT, s (IQR) | 71 (65-79) | 70 (65-77) | 73 (64-81) | 0.52 |
CT < 42 s, n (%) | 1 (2) | 0 | 1 (4) | 0.10 |
CT > 74 s, n (%) | 19 (38) | 8 (32) | 11 (44) | 0.38 |
CFT, s (IQR) | 100 (75-115) | 103 (82-109) | 97 (67-132) | 0.96 |
CFT < 46 s, n (%) | 1 (2) | 0 (0) | 1 (4) | 0.10 |
CFT > 148 s, n (%) | 6 (12) | 1 (4) | 5 (20) | 0.18 |
MCF, mm (IQR) | 57 (51-63) | 58 (53-63) | 52 (46-63) | 0.06 |
MCF <49mm, n (%) | 10 (20) | 0 (0) | 10 (40) | < 0.001 |
MCF >71mm, n (%) | 4 (8) | 2 (8) | 2 (8) | 1.00 |
α-angle, ° (IQR) | 73 (69-77) | 74 (70-76) | 71 (66-80) | 0.31 |
α-angle < 63°, n (%) | 3 (6) | 0 (0) | 3 (12) | 0.23 |
α-angle > 81°, n (%) | 4 (8) | 1 (4) | 3 (12) | 0.60 |
INTEM | ||||
CT, s (IQR) | 197 (183-226) | 195 (181-217) | 202 (185-230) | 0.80 |
CT < 137 s, n (%) | 0 (0) | 0 (0) | 0 (0) | a |
CT > 246 s, n (%) | 9 (18) | 4 (16) | 4 (16) | 1.00 |
CFT, s (IQR) | 92 (69-110) | 91 (80-109) | 91 (62-120) | 0.55 |
CFT < 40 s, n (%) | 1 (2) | 0 (0) | 1 (4) | 1.00 |
CFT > 100 s, n (%) | 22 (44) | 8 (32) | 11 (44) | 0.56 |
MCF, mm (IQR) | 54 (48-59) | 55 (51-59) | 52 (42-59) | 0.16 |
MCF < 52 mm, n (%) | 20 (40) | 8 (32) | 11 (44) | 0.38 |
MCF > 72 mm, n (%) | 1 (2) | 0 (0) | 1 (4) | 1.00 |
α-angle, °(IQR) | 73 (69-76) | 71 (67-75) | 74 (69-80) | 0.55 |
α-angle < 71°, n (%) | 19 (38) | 10 (40) | 9 (36) | 0.77 |
α-angle > 82°, n (%) | 0 (0) | 0 (0) | 0 (0) | a |
FIBTEM | ||||
CT, s (IQR) | 63 (56-71) | 59 (55-65) | 68 (59-79) | 0.004 |
CT < 43 s, n (%) | 0 (0) | 0 (0) | 0 (0) | a |
CT > 69 s, n (%) | 3 (6) | 4 (16) | 9 (36) | 0.19 |
MCF, mm (IQR) | 17 (12-20) | 17 (14-20) | 12 (9-21) | 0.11 |
MCF < 9 mm, n (%) | 4 (8) | 0 (0) | 4 (16) | 0.11 |
MCF > 25 mm, n (%) | 3 (6) | 0 (0) | 3 (12) | 0.23 |
- Citation: Adam EH, Möhlmann M, Herrmann E, Schneider S, Zacharowski K, Zeuzem S, Weber CF, Weiler N. Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis. World J Gastroenterol 2020; 26(17): 2097-2110
- URL: https://www.wjgnet.com/1007-9327/full/v26/i17/2097.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i17.2097